Palatin Technologies (PTN) Income from Continuing Operations (2010 - 2026)
Palatin Technologies' (PTN) quarterly Income from Continuing Operations came in at 1432987.0 in Q1 2026, up 70.04% YoY from 842719.12 in Q1 2025, and up 80.27% on a QoQ basis from 7263861.0 in Q4 2025.
Palatin Technologies (PTN) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Income from Continuing Operations data on file, last reported at 1432987.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 70.04% year-over-year to 1432987.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 6264962.0 (up 73.13% YoY) and the FY2025 annual result came in at 87592274.0, down 194.57% from the prior year.
- Income from Continuing Operations improved to 1432987.0 in Q1 2026, from 7263861.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4677534.0 in Q3 2025 to a low of 12767618.0 in Q2 2022.
- A 5-year average of 5692008.18 and a median of 7263861.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations plunged 1657.47% — and 2025, when it soared 160.77%.
- Tracing PTN's Income from Continuing Operations over 5 years: stood at 6642552.0 in 2022, then fell by 18.09% to 7844034.0 in 2023, then surged by 67.03% to 2586082.0 in 2024, then plunged by 180.88% to 7263861.0 in 2025, then soared by 80.27% to 1432987.0 in 2026.
- The last three Income from Continuing Operations figures came in at 1432987.0 (Q1 2026), 7263861.0 (Q4 2025), and 4677534.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | -1.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.43 Mn |
| Dec 31, 2025 | -7.26 Mn |
| Sep 30, 2025 | 4.68 Mn |
| Jun 30, 2025 | -2.25 Mn |
| Mar 31, 2025 | -4.78 Mn |
| Dec 31, 2024 | -2.59 Mn |
| Sep 30, 2024 | -7.70 Mn |
| Jun 30, 2024 | -8.25 Mn |
| Mar 31, 2024 | -8.44 Mn |
| Dec 31, 2023 | -7.84 Mn |
| Sep 30, 2023 | -6.05 Mn |
| Jun 30, 2023 | -469,449.00 |
| Mar 31, 2023 | -8.67 Mn |
| Dec 31, 2022 | -6.64 Mn |
| Sep 30, 2022 | -8.67 Mn |
| Jun 30, 2022 | -12.77 Mn |
| Mar 31, 2022 | -7.63 Mn |
| Dec 31, 2021 | -8.69 Mn |
| Sep 30, 2021 | -7.40 Mn |
| Jun 30, 2021 | 2.78 Mn |